

□

**Disclaimer: The manuscript and its contents are confidential, intended for journal review purposes only, and not to be further disclosed.**

**URL:** <https://atvb-submit.aha-journals.org>

**Manuscript Number:** ATVB/2017/310097

**Title:** The CANTOS Trial: One Step for Clinical Cardiology but a Giant Leap for Vascular Biology

**Authors:** Gary Owens (Univ. of Virginia School of Medicine), Richard Baylis (Univ. of Virginia School of Medicine), Delphine Gomez (University of Pittsburgh), Ziad Mallat (University of Cambridge), and Gerard Pasterkamp (UMC Utrecht)

For ATVB Peer Review. Do not distribute after use.

## The CANTOS Trial: One Step for Clinical Cardiology but a Giant Leap for Vascular Biology

Richard A. Baylis<sup>1,2</sup>, Delphine Gomez<sup>3,4</sup>, Ziad Mallat<sup>5,6</sup>, Gerard Pasterkamp<sup>7</sup>, Gary K. Owens<sup>1,8\*</sup>

**Affiliation:**

1. Robert M. Berne Cardiovascular Research Center, University of Virginia
2. Department of Biochemistry and Molecular Genetics, University of Virginia
3. Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh
4. Division of Cardiology, University of Pittsburgh School of Medicine; Pittsburgh, PA, USA.
5. Division of Cardiovascular Medicine, University of Cambridge
6. Institut National de la Santé et de la Recherche Médicale, Paris Cardiovascular Research Center
7. Laboratory of Clinical Chemistry, University Medical Centre Utrecht, Utrecht University
8. Department of Molecular Physiology and Biological Physics, University of Virginia

**\*Corresponding Author:** Gary K. Owens  
University of Virginia School of Medicine  
415 Lane Road, P.O. Box: 801394  
Room 1332, Medical Research Building 5  
Charlottesville, VA 22908  
Phone: 434-924-2652  
Fax: 434-982-0055  
Email: [gko@virginia.edu](mailto:gko@virginia.edu)

**Running Title:** "Implications of the CANTOS trial for Vascular Biology"

**Keywords:** Atherosclerosis, Coronary Artery Disease, Translational Research, Inflammation, Interleukin-1 $\beta$

**Summary:** The results of the CANTOS trial provide exciting evidence in support of the inflammatory hypothesis of atherosclerosis in humans, and is the first phase III clinical trial to show clinical benefit of a targeted anti-inflammatory therapy. However, the modest overall clinical benefit and safety concerns with increased susceptibility to fatal infections indicate that we need much more work in this critical area.

The importance of inflammation in atherosclerosis has been a topic of basic research for several decades. However, despite a clear link between inflammation and atherosclerosis in contemporary vascular biology, clinical data demonstrating a direct benefit of targeting inflammation on patient outcomes has been absent – until now. The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS)<sup>1</sup> was a randomized, double-blinded, placebo-controlled trial that investigated the use of canakinumab, a monoclonal antibody targeting IL-1 $\beta$ , on high-risk patients with established atherosclerotic disease who had already survived a myocardial infarction (MI). To be included in the trial, each patient needed to have residual inflammatory risk, meaning that subjects had elevated biomarkers of inflammation despite standard of care therapy. The treatment was administered quarterly at three different doses (50, 150, and 300-mg). All doses significantly lowered the inflammatory burden (a 26, 37, and 41% reduction in hsCRP for the corresponding doses) and, importantly, had no impact on LDL cholesterol. However, only the 150-mg dose succeeded in reducing the primary endpoint (non-fatal MI, stroke, or cardiovascular [CV] death) by 15% ( $p=0.02074$ ) meeting the trial's pre-specified significance threshold of 0.02115. The overall effect was a reduction in the incidence of a recurrent CV event from 16% in the placebo-treated group, to 14% in the 150-mg canakinumab group during the median 3.7 year follow up. Interestingly, this outcome was primarily the result of reduced recurrent MI with no significant change in non-fatal stroke, CV death, or all-cause mortality. The latter was due to offsetting effects of reduced cancer mortality but increased fatal infections. Therefore, as suggested in an insightful editorial<sup>2</sup> by Robert Harrington, despite CANTOS being the first study to show that targeting inflammation can confer modest cardiovascular benefit in very high-risk patients, the safety concerns and potentially prohibitive cost make it unclear whether canakinumab will ultimately be used as a secondary prevention following MI. Nevertheless, the results do provide an exciting glimpse at the potential for using anti-inflammatory therapies for treating cardiovascular disease. However, to do so we must: 1) identify safer and more efficacious strategies before considering widespread use of anti-inflammatory therapies to lower-risk patients; and/or 2) find ways to identify subsets of patients who will derive maximum benefits from canakinumab (or other anti-inflammatory agents) but who are at low risk for serious infections. We feel that the best path toward achieving this goal is to increase our basic understanding of not only the negative but also of the potential positive roles of inflammation in atherosclerosis. In this rapid review, we will critically evaluate the CANTOS results and try to identify the challenges facing the vascular biology field moving forward.

**Interpreting the Mode of Lesion Failure:**

Although not reported in the original paper<sup>1</sup>, it would be interesting to know what subset of MI was benefited (ST-elevation or non-ST-elevation MI), which could give us a hint as to the modus of atherosclerosis complication. Specifically, whether the canakinumab-treated patients were more protected from plaque erosion or plaque rupture events. In CANTOS, 91% of patients were on statin therapy and the mean LDL cholesterol was relatively well-controlled at 82 mg/dL. Current literature would suggest that these factors may skew these patients to be at relatively higher risk for plaque erosion rather than rupture.<sup>3</sup> Further evidence for this trend may be gleaned from the more statistically robust results when unstable angina with urgent revascularization was included in the analysis, suggesting that partially occlusive events like NSTEMI and unstable angina may have disproportionately benefited. Unfortunately, our current experimental models in hypercholesterolemic mice fail to emulate many of the key features of plaque erosion (i.e., endothelial desquamation, neutrophil recruitment, few macrophages, and small necrotic core).<sup>4</sup> However, a recent study found that a combination of vascular injury followed by flow disruption recapitulated many of the characteristics of eroded plaques, a strategy that may be a valuable tool to probe anti-inflammatory therapies moving forward.<sup>5</sup> It is important to note that even if there were a trend toward reduced relative risk of plaque erosion in these patients, plaque rupture of thin-capped fibroatheromas (TCFAs) – also known as “vulnerable plaques” – remains the primary modality for atherosclerosis complications and still requires extensive research focus. Estimates on the prevalence of plaque erosion and rupture vary, but even aggressive estimates suggest that rupture remains the primary driver of plaque failure. Indeed, a ruptured fibrous cap is found in ~2/3 of post-mortem samples from patients dying of an acute coronary syndrome<sup>4</sup> and intravascular imaging has shown that plaque rupture accounts for ~71% and 43% of ST and non-STEMI, respectively.<sup>3</sup> Although the PROSPECT study showed that only 5% of TCFAs resulted in a clinical event in 3.4 years, TCFA plaque morphology was the *only* independent risk factor that was predictive for a future event.<sup>6</sup> This latter observation emphasizes the point that major adverse cardiovascular events are relatively rare, but they are still much more likely to occur at high-risk TCFAs. As an analogy, being struck by lightning may be an extraordinarily rare event, but it is still unwise to hold a metal rod in the air during a lightning storm. Both modes of lesion failure have critical clinical importance, and although it is suggested that over time erosion is becoming more prevalent as a pathological substrate of an acute myocardial infarction,<sup>3</sup> it is too soon to write off rupture such that future studies of potential anti-inflammatory agents need to examine both of these processes.

**Preclinical Study of Residual Inflammatory Risk:**

Another interesting characteristic of the CANTOS trial that alludes our current preclinical models is the concept of residual inflammatory risk.<sup>7</sup> Lipid lowering therapies are the mainstay of managing high-risk CV patients and pioneering results from the PROVE-IT and JUPITER trials suggest that most CV patients should be on high-intensity statin therapy, meaning that the average patient has more than a 50% reduction in their LDL cholesterol level.<sup>8,9</sup> In addition, these studies revealed a potent anti-inflammatory benefit of statin therapy. However, despite the potent benefit of high-intensity statins, there are subsets of patients that retain elevated levels of inflammatory biomarkers like hsCRP, which portend a high risk for future clinical events. This scenario is referred to as residual inflammatory risk and falls in stark contrast to our cholesterol-driven mouse models of atherosclerosis, which require simultaneous genetic and dietary manipulations to induce extraordinarily high cholesterol levels. Therefore, apart from the inflammation caused by excessive cholesterol burden, current mouse atherosclerosis models in general fail to adequately mimic the elevated systemic inflammation that defines this patient population. One possible course would be to further manipulate mice to more closely match the clinical situation (e.g., inciting inflammation with surgically-induced MI or chemically-induced peritonitis), but no matter how hard we try, our mice will remain mice. Key barriers include: 1) the many obvious differences between mice and humans (e.g., genetics, immune systems, diet, lifespan, microbiomes, comorbidities, etc.); 2) the timeline of years to decades of atherosclerosis development, progression, and treatment in humans versus weeks to months in our mouse models; and 3) an inability to account for effects of current treatments in humans including aggressive lipid lowering, anti-thrombotic therapies, and invasive and non-invasive anti-ischemic interventions (i.e., coronary bypass or angioplasty). Indeed, as clinical trials further select for the highest risk patient subsets, our animal models are likely to become increasingly incapable of properly modeling their complications even with heroic well-intended efforts.

Nevertheless, our simplified models can be extremely valuable for testing hypotheses that derive from human studies and clinical trials such as CANTOS, and for attempting to identify new and more effective therapeutic targets. However, the CANTOS trial results further drive home the need for us to continue to try to better match animal models to the CV disease and clinical need of interest, and for investigators to put much more emphasis on performing human validation studies. For example, we recently used a novel single cell epigenetic method developed in our lab to show that nearly a third of the cells within advanced human coronary artery lesions presumed to be macrophages based on expression of CD68, are actually of SMC

rather than myeloid origin thus validating our initial discovery of SMC-derived macrophage-like cells observed in SMC lineage-tracing mouse studies.<sup>10</sup> Indeed, the results of CANTOS need to drive hypotheses for future animal studies aimed at identifying better therapies for treating advanced atherosclerosis.

### **Determining the Mechanism of the Benefit:**

As we continue to probe for mechanisms by which neutralizing IL-1 $\beta$  improved cardiovascular outcomes, fundamental questions remain. For example, it is unclear whether the benefits were driven by reductions in systemic inflammation or locally within the plaque. The systemic effect of IL-1 $\beta$  neutralization could manifest as improved metabolic parameters, reduced platelet activation, and/or leukocyte mobilization from the bone marrow. Indeed, in the Novartis press release on August 27th (<https://www.novartis.com/news/media-releases/novartis-phase-iii-cantos-study-demonstrates-targeting-inflammation-acz885>), they reported no benefit regarding new onset diabetes. However, there is a large body of preclinical evidence to suggest an overall benefit of inhibiting IL-1 signaling on pancreatic islet health and homeostasis,<sup>11</sup> although as yet data are unclear as to whether canakinumab treatment confers improved glycemic control and insulin sensitivity, and if so, in what patient populations.<sup>12,13</sup> In addition, a previous study by Sager et al. showed reduced post-MI leukocytosis when mice were given a murine version of canakinumab.<sup>14</sup> Despite well-characterized benefits systemically, there exists a paucity of information regarding the impact of IL-1 $\beta$  neutralization on the lesions themselves, particularly on key cell types thought to regulate plaque stability (i.e., SMC, macrophage, and endothelial cells). A study from our lab using global IL-1 receptor 1 knockout mice suggested that IL-1 signaling promoted several beneficial processes during atherosclerosis development including collagen synthesis and SMC investment into the fibrous cap.<sup>15</sup> However, we still do not know the impact of disruption of IL-1 signaling on established atherosclerotic lesions and there remains a lot of confusion about how different lesion cell types may respond. For example, in the discussion of the CANTOS results, the authors highlight one of the roles for IL-1 signaling is to promote SMC proliferation, a process that we believe has been incorrectly assumed by many in the field to be detrimental. We believe this concept resulted from an inappropriate extrapolation of early studies of in-stent restenosis where SMC proliferation would eventually result in vessel stenosis and the need for revascularization. However, this interpretation is not applicable to advanced atherosclerotic lesions where SMC enrichment – especially within the fibrous cap – is universally considered beneficial. However, even this interpretation is overly simplistic as we now have good evidence that SMC can perform a multitude of functions within

the lesion and that their overall impact on lesion stability can be beneficial or detrimental depending on the nature of their phenotypic and associated functional transitions.<sup>16-18</sup> However, this confusion highlights the critical need for increased understanding of the impact of anti-inflammatory strategies on all major lesion cell types and, especially, on extracellular matrix-producing cells responsible for forming a protective fibrous cap.

### **Avoiding the Adverse Effects of Anti-inflammatory Therapies:**

The IL-1 $\beta$  signaling pathway and inflammation are critical for many protective processes including infection and wound healing that clearly did not evolve to increase our risk of CV disease. Instead, it is the dysregulation of well-intended processes like oxidized-lipid clearance and macrophage egress that promotes atherosclerosis.<sup>19,20,21,22</sup> Thus, assuming IL-1 signaling regulates both detrimental and beneficial processes may help explain both the modest overall benefits of canakinumab but also the interesting dosing effects. Specifically, the cancer data published in the Lancet<sup>23</sup> and the rate of infections show clear dose-dependent changes with IL1 $\beta$  neutralization, suggesting that IL1 signaling is not saturated. In contrast, the cardiovascular benefit failed to show a similar dose response for CV outcomes (i.e., the 150 and 300-mg doses resulted in equivocal results). The failure of the 300-mg dose to reach statistical significance is, in part, due to complicated hierarchical statistical analyses, but a closer look reveals that several of the outcome measures actually fared worse at the highest dose (e.g., MI had a relative risk reduction of 24% at 150-mg and 16% at 300-mg). It is therefore possible that at this dose the benefit of inhibiting harmful inflammatory processes is offset by also preventing beneficial ones. Indeed, this is reminiscent of a previous murine study testing IL1 $\beta$  neutralization at three different doses on atherosclerosis development in which they also found that beneficial changes in lesion characteristics (i.e., CD68 and lipid staining) only occurred at the middle dose of treatment.<sup>24</sup> This highlights that we still have a lot to learn about the processes regulated by inflammation and places the onus on vascular biologists to determine strategies that inhibit the detrimental effects of inflammation while retaining and promoting the beneficial processes. In this regard, modulation of antigen-specific adaptive immune responses may be well suited to selectively target pro-atherogenic responses while preserving other protective processes like host-defense and wound healing.

### **Identifying Responder from Non-Responders:**

The CANTOS authors note that, if patients are divided at the median of hsCRP response, the patients that fall in the upper half of hsCRP reduction – the responders – had a

27% reduction in cardiovascular events compared to only 5% for the lower half. The authors suggest that a trial dose of canakinumab could be used to determine if a patient has adequate hsCRP reduction to justify continuing their treatment. However, the problem is more complex than this – we must also be able to identify those most at risk for the potential harmful effects of anti-IL1 $\beta$  treatment including fatal infection. As such, a challenge for future studies is to determine genetic and epigenetic mechanisms that influence responsiveness to anti-IL1 $\beta$  treatment, and other screening methods (e.g., more informative biomarkers) that can better identify which patients will benefit and which will not. One intriguing possibility was recently identified by Fuster et al.<sup>25</sup> who studied how cumulative mutations in hematopoietic stem cells (HSC) that contribute to clonal selection of HSC in elderly individuals can significantly impact atherosclerosis development by modifying the function of myeloid cells. Of major interest, they showed that one of the most prevalent mutations in human HSC, Tet2, could drive clonal selection in LDL receptor KO mice. Interestingly, these mutations markedly exacerbated atherosclerosis development which was accompanied by enhanced IL-1 $\beta$  production by macrophages. As we look to the future, it will be interesting if this becomes a part of our personalized approaches to cardiovascular care, where patients with pro-atherogenic clonal hematopoiesis are more aggressively targeted with anti-inflammatory medications. Obviously, this is just one of many other possibilities to consider.

### **Looking for Benefits in other Disease Contexts:**

Inflammation has been implicated in a diverse array of human pathologies. Perhaps the most exciting observation of CANTOS is the 77% reduction in lung cancer fatality.<sup>23</sup> Although previous cancer diagnosis was among the exclusion criteria for the trial, the age and medical history of the patients put them at high risk for cancer development and, consequently 6.5% of patients were diagnosed with cancer during the trial. For example, the patients that eventually developed lung cancer had an average age of 65 and more than 90% had a smoking history. Indeed, cardiovascular disease and certain cancers share a host of risk factors including elevated hsCRP. The authors suggest that the benefit was unlikely due to preventing new cancers but rather inhibiting the progression and eventual metastasis of previously undiagnosed cancers. The results will need to be repeated in a formal cancer clinical trial but these initial data are quite exciting. Perhaps this reveals an important lesson for researchers that as we continue to make progress on anti-inflammatory therapies for cardiovascular disease, we should be vigilant for data that may support a benefit of therapy in another disease context. It is a provocative concept that one preventative medication could yield protection from an array of



human diseases – perhaps this is the best chance for canakinumab. Patients at high-risk of lung cancer could be treated and be promised both a profound benefit for cancer mortality and also reduced risk for cardiovascular disease.

In summary, the CANTOS trial is an exciting conclusion to the first chapter of a decades-long investigation of the inflammatory hypothesis of atherosclerosis. Thanks to the seminal work from many pioneering vascular biologists, clinical trialists, and Novartis, we have clinical outcome data showing a clear benefit of targeting inflammation in high-risk CV patients. However, many large questions remain – what is the impact of canakinumab on plaque stability, how can we avoid inhibiting beneficial inflammatory processes like host defense, how can we better identify patients that would most benefit from these therapies? The pursuit of these questions will hopefully reveal more efficacious and safer therapies. For now, we must celebrate this trial for its significant scientific impact, having revealed inflammation as a viable and likely fertile path toward improved atherosclerosis management, but commit ourselves to better understanding the vascular impacts of targeting inflammation.

**Disclosures:** The Owens lab has collaborated with Novartis on studies in mice and have received antibodies.

#### References:

1. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med.* 2017;
2. Harrington RA. Targeting Inflammation in Coronary Artery Disease. *N Engl J Med.* 2017;
3. Pasterkamp G, Ruijter den HM, Libby P. Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease. *Nature Publishing Group.* 2017;14:21–29.
4. Kanwar SS, Stone GW, Singh M, Virmani R, Olin J, Akasaka T, Narula J. Acute coronary syndromes without coronary plaque rupture. *Nature Publishing Group.* 2016;13:257–265.

5. Franck G, Mawson T, Sausen G, Salinas M, Masson GS, Cole A, Beltrami-Moreira M, Chatzizisis Y, Quillard T, Tesmenitsky Y, Shvartz E, Sukhova GK, Swirski FK, Nahrendorf M, Aikawa E, Croce KJ, Libby P. Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in Mice: Implications for Superficial Erosion. *Circulation Research*. 2017;121:31–42.
6. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW, PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med*. 2011;364:226–235.
7. Ridker PM. How Common Is Residual Inflammatory Risk? *Circulation Research*. 2017;120:617–619.
8. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med*. 2004;350:1495–1504.
9. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195–2207.
10. Gomez D, Shankman LS, Nguyen AT, Owens GK. Detection of histone modifications at specific gene loci in single cells in histological sections. *Nat Methods*. 2013;10:171–177.
11. Herder C, Dalmas E, Böni-Schnetzler M, Donath MY. The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications. *Trends Endocrinol Metab*. 2015;26:551–563.
12. Choudhury RP, Birks JS, Mani V, Biasioli L, Robson MD, L'Allier PL, Gingras M-A, Alie N, McLaughlin MA, Basson CT, Schechter AD, Svensson EC, Zhang Y, Yates D, Tardif J-C, Fayad ZA. Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance. *J Am Coll Cardiol*. 2016;68:1769–1780.
13. Rissanen A, Howard CP, Botha J, Thuren T, Global Investigators. Effect of anti-IL-1 $\beta$  antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. *Diabetes Obes Metab*. 2012;14:1088–1096.
14. Sager HB, Heidt T, Hulsmans M, Dutta P, Courties G, Sebas M, Wojtkiewicz GR, Tricot B, Iwamoto Y, Sun Y, Weissleder R, Libby P, Swirski FK, Nahrendorf M. Targeting Interleukin-1 $\beta$  Reduces Leukocyte Production After Acute Myocardial

- Infarction. *Circulation*. 2015;132:1880–1890.
15. Alexander MR, Moehle CW, Johnson JL, Yang Z, Lee JK, Jackson CL, Owens GK. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. *J Clin Invest*. 2012;122:70–79.
  16. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, Swiatlowska P, Newman AAC, Greene ES, Straub AC, Isakson B, Randolph GJ, Owens GK. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. *Nature Medicine*. 2015;21:628–637.
  17. Cherepanova OA, Gomez D, Shankman LS, Swiatlowska P, Williams J, Sarmiento OF, Alencar GF, Hess DL, Bevard MH, Greene ES, Murgai M, Turner SD, Geng Y-J, Bekiranov S, Connelly JJ, Tomilin A, Owens GK. Activation of the pluripotency factor OCT4 in smooth muscle cells is atheroprotective. *Nature Medicine*. 2016;22:657–665.
  18. Bennett MR, Sinha S, Owens GK. Vascular Smooth Muscle Cells in Atherosclerosis. *Circulation Research*. 2016;118:692–702.
  19. Libby P. Inflammation in atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2012;32:2045–2051.
  20. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. *Nat Rev Immunol*. 2010;10:36–46.
  21. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. *Nat Rev Immunol*. 2013;13:709–721.
  22. Randolph GJ. Emigration of monocyte-derived cells to lymph nodes during resolution of inflammation and its failure in atherosclerosis. *Curr Opin Lipidol*. 2008;19:462–468.
  23. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, CANTOS Trial Group. Effect of interleukin-1 $\beta$  inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet*. 2017;
  24. Bhaskar V, Yin J, Mirza AM, Phan D, Vanegas S, Issafras H, Michelson K, Hunter JJ, Kantak SS. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. *Atherosclerosis*. 2011;216:313–320.
  25. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu C-L, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AAB, Cooper MA, Andrés V, Hirschi KK, Martin KA, Walsh K. Clonal

hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science*. 2017;355:842–847.

For ATVB Peer Review. Do not distribute. Destroy after use.